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Epstein–Barr virus (EBV) infection of B cells is associated with increased multiple scle-
rosis (MS) susceptibility. Recently, we found that CXCR3-expressing B cells preferentially
infiltrate the CNS of MS patients. In chronic virus-infected mice, these types of B cells are
sustained and show increased antiviral responsiveness. How EBV persistence in B cells
influences their development remains unclear. First, we analyzed ex vivo B-cell subsets
from MS patients who received autologous bone marrow transplantation (n = 9), which is
often accompanied by EBV reactivation. The frequencies of nonclass-switched and class-
switched memory B cells were reduced at 3–7 months, while only class-switched B cells
returned back to baseline at 24–36 months posttransplantation. At these time points, EBV
DNA load positively correlated to the frequency of CXCR3+, and not CXCR4+ or CXCR5+,
class-switched B cells. Second, for CXCR3+ memory B cells trapped within the blood of
MS patients treated with natalizumab (anti-VLA-4 antibody n = 15), latent EBV infection
corresponded to enhanced in vitro formation of anti-EBNA1 IgG-secreting plasma cells
under GC-like conditions. These findings imply that EBV persistence in B cells potentiates
brain-homing and antibody-producing CXCR3+ subsets in MS.
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Introduction
The success of anti-CD20 therapy puts forward B cells as
important players of autoimmune diseases including multiple
sclerosis (MS) [1]. The strongest infectious risk factor for MS is
the Epstein–Barr virus (EBV) [2, 3], a DNA γ-herpes virus that
infects and persists within B cells using a series of programs
that mimic germinal center (GC) differentiation signals [4]. In
MS, one of the hypotheses is that EBV remains latent within
pathogenic memory B cells that invade the central nervous sys-
tem (CNS) [3, 5]. Once in the CNS, pathogenic memory B cells
are likely reactivated and further develop into antibody-secreting
plasma cells to mediate local inflammation [1]. IL-21 and CD40L
are the main triggers of plasma cell differentiation during a GC
response [6, 7]. However, in murine models of autoimmune dis-
eases this response seems to be dysregulated in the presence of
IFN-γ [8].
IFN-γ triggering of B cells induces the T-box transcription fac-
tor T-bet, which drives the surface expression of CXC chemokine
receptor (CXCR)3 [9]. Recently, our group found that CXCR3-
expressing B cells are abundant in the MS CNS and selectively
accumulate in the blood of MS patients treated with natalizumab
(NTZ; anti-VLA-4 mAb) [10], an effective drug that prevents their
infiltration into the CNS. Moreover, naive B cells of untreated
MS patients preferentially developed into CXCR3-expressing plas-
mablasts under IL-21-, CD40L-, and IFN-γ-inducing conditions in
vitro [10]. Interestingly, in mice, CXCR3(T-bet)-expressing B cells
do not only show increased antiviral responses, but are also more
sustained during chronic viral infections [11]. How EBV infection
contributes to the development of pathogenic memory B cells is
poorly understood.
Here, we used two distinct MS cohorts to determine the associ-
ation of B-cell EBV DNA load with CXCR3+ memory B-cell devel-
opment. First, memory B-cell subsets were studied ex vivo from
MS patients who received autologous bone marrow transplanta-
tion (BMT), which is often accompanied with EBV reactivation
[12, 13]. Second, GC-like plasma cell differentiation was explored
in vitro for memory B cells trapped within the blood of NTZ-
treated MS patients, who are known to experience a massive local
influx of EBV-infected B cells after treatment cessation [14].
Results and discussion
EBV load corresponds to CXCR3 expression in
class-switched memory B cells of BMT-treated MS
patients
To address the specific relation between EBV load and CXCR3+
B-cell induction, we explored the distribution, EBV load, and
chemokine receptor profiles of ex vivo B-cell subsets within
the blood of nine MS patients after autologous BMT (Support-
ing Information Table S1) [15]. The proportions of transitional
(CD38highCD27–) B cells were increased at 3–7 months and
reduced to baseline levels at 24–36 months, while those of naive
Figure 1. Reconstitution and EBV load of B-cell subsets in the blood of
autologous BMT-treatedMS patients. (A) Flow cytometry gating strategy
used to define transitional (CD38highCD27–; Btrans), naive mature (CD27
–IgM+; Bnm), nonclass-switched memory (CD27+IgM+; NCS Bmem), and
class-switched memory (IgM–IgD–; class-switched [CS] Bmem) within
blood CD19+ B cells. (B) Quantification of B-cell subset frequencies in
the blood of MS patients before (black dots) and both 3–7 months (dark
gray dots) and 24–36 months (light gray dots) after receiving autologous
BMT (paired samples; n = 9; Supporting Information Table S1). (C) EBV
DNA load in sorted Bnm,NCS Bmem, and CS Bmem cells before and both 3–
7 and 24–36 months after BMT (n = 9; copies/1 × 106 cells). Flow cytom-
etry data weremeasured and B cell subsets were sorted in five indepen-
dent experiments, with paired time points for one to two patients per
experiment. EBV DNA load was determined by qPCR in three indepen-
dent experiments, with paired time points for three to five patients per
experiment. Data are presented as the mean ± SEM. **p < 0.01 and *p <
0.05. The p values in (B) were calculated by repeated measures one-way
ANOVA with Tukey’s post hoc test.
mature (CD38–/dimIgM+CD27–) B cells remained unaltered post-
BMT (Fig. 1A and B). Both Ig class-switched (IgM–IgD–) and
nonclass-switched (IgM+CD27+) memory B cells were decreased
at 3–7 months, and only class-switched B cells returned to base-
line levels at 24–36 months post-BMT (Fig. 1A and B). After
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purifying these subsets, high EBV copy numbers were measured
for class-switched B cells at 3–7 months post-BMT (Fig. 1C),
at the timeframe in which low numbers of memory B cells are
present in the blood. This is in line with previous studies using
allogeneic stem cell transplants [16, 17]. EBV levels in class-
switched B cells were increased for five patients and reduced for
four patients when comparing 3–7 months post- to pre-BMT sam-
ples. These changes in EBV load strongly corresponded to the
expression of CXCR3 (Fig. 2A and B). Although immunomodu-
latory treatment was discontinued at least 1 month before BMT,
six patients were previously treated with interferon-beta (IFN-
β) or IFN-β together with intravenous immunoglobulin (IVIG)
[15]. Nevertheless, EBV load and CXCR3 expression in class-
switched B cells were similar to patients without previous treat-
ment (Supporting Information Fig. S1 and Table S1). Taking all
individual samples into account, we found a positive correlation
between EBV load and CXCR3+, but not CXCR4+ or CXCR5+ frac-
tions of class-switched B cells (Fig. 2C and D). This was par-
ticularly significant for 3–7 months post-BMT samples and not
seen in pre-BMT samples (Supporting Information Fig. S2A) or
in blood samples from healthy controls (Supporting Information
Fig. S2B). Despite the lower levels of EBV, similar trends were
observed in nonclass-switched B cells (Supporting Information
Fig. S3A). In contrast to nonclass-switched B cells, EBV load pos-
itively correlated to the expression of activation markers CD69
and CD95 in class-switched B cells (Supporting Information Fig.
S3B). Notably, three out of four BMT-treated patients whose mem-
ory B cells showed decreased EBV and CXCR3 levels had sta-
ble or improved disability scores during 36 months follow-up as
reflected by expanded disability status scale score and ambulatory
index (Fig. 2E) [15]. In BMT-treated patients with an increase
in memory B cell EBV and CXCR3 levels, an increased disability
was observed in four out of five and five out of five participants,
respectively.
Overall, these findings implicate that the high EBV levels found
after autologous BMT in MS patients induces the development of
CXCR3+ memory B cells and is possibly related to clinical worsen-
ing. CXCR3 upregulation through EBV infection may be caused by
a disturbed immune system [18], and contribute to the increased
recruitment of pathogenic B cells and the formation of follicle-like
structures in the MS CNS [10, 19].
EBVhigh memory B cells of NTZ-treated MS patients
preferentially develop into CXCR3+ plasma cells
EBV mainly persists within GC-derived memory B cells, which
subsequently differentiate into antibody-secreting plasma cells
[4]. After NTZ treatment, MS patients show increased numbers
of CXCR3+ memory B cells in the blood, which are normally
recruited and further differentiate into plasma cells in the CNS
[10, 20]. Hence, blood samples from these patients offer a unique
opportunity to assess the relation between latent EBV infection
and plasma cell development of potentially CNS-infiltrating mem-
ory B cells. To determine this, we screened EBV load in different
blood samples from 15 MS patients treated with NTZ for 1–4
years. Of these patients, one showed an increase, one a decrease,
and the remainder a stable expanded disability status scale score
over the course of 36 months after sampling (Supporting Infor-
mation Table S1). Ten samples with >1000 copies per 1 × 106
cells (EBVhigh) and eight samples with <500 copies per 1 × 106
cells (EBVlow) were selected for our in vitro differentiation study.
CD27+ memory B cells were cultured under IL-21- and CD40L-
stimulating (GC-like) conditions for 6 days and differentiation
into plasma cells (CD38highCD27highCD138+) was compared with
and without the addition of IFN-γ (Fig. 3A and B). Under these
circumstances, total and CXCR3+ plasma cells were found to
be more induced in the EBVhigh versus the EBVlow group, which
was most pronounced in cultures containing IFN-γ (p = 0.023
and p = 0.011, respectively; Fig. 3C and D). For nine out of ten
samples from the EBVhigh group, CXCR3+ plasma cell frequencies
were higher under IFN-γ-inducing conditions than those from
a healthy reference group (n = 6; dotted line), which was the
case for two out of six samples from the EBVlow group. B-cell EBV
load correlated to CXCR3+ plasma cell outgrowth in IL-21- and
IFN-γ-induced samples (Fig. 3E). This agrees with a mouse study
showing that enhanced CXCR3 expression results in aberrant
plasma cell development within GCs [9]. Both surface CXCR3
and intracellular T-bet levels were further triggered by IFN-γ
during these cultures, but were not different between EBVhigh
and EBVlow groups (Supporting Information Fig. S4A). Finally,
the ability of in vitro induced plasma cells to secrete anti-EBV
nuclear antigen 1 (anti-EBNA1) IgG positively correlated with the
expression of CXCR3 (Fig. 3F) and T-bet (Supporting Information
Fig. S4B).
Concluding remarks
In this study, we reveal that high EBV load is associated with
(1) early emergence of CXCR3+ class-switched memory B cells
from autologous BMT-treated MS patients, and (2) enhanced in
vitro generation of CXCR3+ plasma cells from memory B cells
trapped in the blood of NTZ-treated MS patients. Although we
did not show the dependence of memory B-cell development on
CXCR3 in these settings, there is a clear relation between CXCR3
expression and GC-like B-cell development [9] and recruitment to
the CNS [21] in virus-infected mice. Based on our findings, EBV
load is related to the development of CXCR3+ memory B cells
into plasma cells, while the expression of CXCR3 by these plasma
cells seems to enhance their ability to secrete anti-EBNA1 IgG.
This not only links to the predictive value and intrathecal detec-
tion of anti-EBV antibodies [22, 23], but also contributes to the
ongoing debate about the local presence of EBV-infected B cells
in MS [24]. CXCR3+ B cells may also strongly respond to other
viruses implicated in MS [11, 25]. Subsequent studies should be
performed to verify whether the impact of EBV load on CXCR3+
B-cells is a general feature of MS regardless of disease-modifying
treatment.
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Figure 2. The association between EBV load and chemokine receptor expression in class-switched B cells of BMT-treatedMS patients. (A) Represen-
tative flow cytometry plots of CXCR3-expressing class-switched (CS) Bmem cells from an MS patient before and both 3–7 months and 24–36 months
after autologous BMT. EBV copy numbers measured by qPCR and frequencies of CXCR3+ (B) as well as CXCR5+ (C) fractions were determined for
CS Bmem cells of nine BMT-treated MS patients. (D) EBV copy numbers were correlated to CXCR3+, CXCR4+, and CXCR5+ fractions of CS Bmem cells.
Data were collected in the same number of experiments as depicted in Figure 1. (E) Expanded disability status scale (EDSS) and ambulatory index
(AI) changes after BMT treatment ( pre- vs. 36 months post-BMT) for patients showing increased (n = 5) and decreased (n = 4) memory B-cell EBV
loads and measured by questionnaires. **p < 0.01. The p values were calculated by repeated measures one-way ANOVA with Tukey’s post hoc test
(B and C) and correlation coefficient by Pearson rank (D).
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Figure 3. In vitro plasma cell formation of memory B cells from NTZ-treated MS patients with different B-cell EBV load. (A) Experimental setup of
the GC-like memory B-cell differentiation assay. CD27+ memory B cells (Bmem) were sorted from different blood samples of a total of 15 NTZ-treated
MS patients (Supporting Information Table S1) and cultured under IL-21-/CD40L-inducing (GC-like) conditions for 6 days. (B) Representative flow
cytometry gating strategy for the analysis of in vitro differentiated plasma cells within viable CD19+ cells after 6 days of culturing. Plasma cell
development was analyzed for NTZ-treated MS patients with high and low B-cell EBV load (n = 6–10) under conditions with and without IFN-γ (C
and D). Dotted lines indicate the mean frequencies of each population analyzed for simultaneous in vitro cultures with memory B cells of six age-
and gender-matched healthy controls. In vitro cultures and flow cytometry data were collected in six independent experiments, with one to two
EBVhigh and one to two EBVlow MS patients, as well as one healthy control per experiment. (E) Correlation between EBV copy numbers and fractions
of in vitro induced CXCR3+ plasma cells. (F) Correlation between anti-EBNA1 IgG secretion and CXCR3 surface expression by in vitro differentiated
plasma cells. Anti-EBNA1 IgG was measured in four independent experiments with two to six patient samples per experiment and each sample
was measured in duplicate. Data are presented as the mean ± SEM. *p < 0.05. The p values were calculated by Mann–Whitney U (D) and correlation
coefficients by Spearman rank (E and F) tests.
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Materials and methods
Patients
Characteristics of patients used in this study are summarized in
Supporting Information Table S1. For the analysis of EBV infection
in relation to ex vivo B-cell subsets, we used nine MS patients who
had undergone autologous BMT as previously described [15].
In short, CD34+ stem cells were isolated from BM and cryopre-
served until use. These patients obtained a vigorous T-cell deple-
tion regimen consisting of ATG (anti-thymocyte globulin) and
total body irradiation before treatment with the preserved stem
cells [15]. For each patient, thawed peripheral blood mononu-
clear cells (PBMCs) were analyzed before and both 3–7 and 24–
36 months after BMT. Previous immunomodulatory drugs were
discontinued at least 1 month prior to BMT (see also Support-
ing Information Fig. S1). ATG was given to patients 3–7 days
before BMT [15]. PBMCs were isolated from six patients within 1
month and from three patients within 3 months before BMT. For
all patients, PBMCs were collected before the start of ATG treat-
ment. For the analysis of EBV load in relation to CXCR3+ B-cell
differentiation in vitro, we used thawed PBMCs of MS patients
treated with NTZ (anti-VLA-4 antibody; 1–4 years posttreatment)
[10]. These patients were both age- and gender-matched with
healthy controls. Study protocols were approved by the medical
ethics committee of the Erasmus Medical Center (Rotterdam, The
Netherlands) and all patients gave written informed consent [15,
26].
Cell isolation, antibodies, and flow cytometry
PBMCs were isolated from blood of patients using Ficoll®-
Paque Plus (GE Healthcare, Freiburg, Germany) and density
centrifugation or with vacutainer CPT® tubes (BD Biosciences,
Erembodegem, Belgium) and stored in liquid nitrogen until use as
earlier reported [10]. FACS was performed on PBMCs using mon-
oclonal antibodies as indicated in Supporting Information Table
S2. Cells were stained extracellularly for 30 min at 4°C. Prior
to extracellular staining, cultured memory B cells were labeled
with a viability stain (FVS700) for the analysis of viable cells. All
measurements were performed on a LSRII-Fortessa machine and
analyzed using FACS Diva software, version 8.0.1 (both BD Bio-
sciences). B-cell subsets were separated using a FACSAria III cell
sorter (BD Biosciences) for qPCR analysis or in vitro cultures.
DNA isolation and EBV load qPCR
DNA was extracted using a GenEluteTM Mammalian Genomic
DNA Miniprep Kit according to the manufacturer’s instructions
(Sigma-Aldrich via Merck, Kenilworth, NJ, USA). EBV DNA load
was determined using a multiplex RQ-PCR assay using a FAM-
labeled probe specific for BALF5 (the EBV DNA polymerase; Euro-
gentec, Liège, Belgium) and a VIC-labeled probe specific for ref-
erence gene beta-2 microglobulin (B2M; Thermo Fisher Scien-
tific, Landsmeer, The Netherlands) [27, 28]. Primer and probe
sequences and used concentrations are shown in Supporting
Information Table S3. We added 5 μL (200 ng) DNA to 20 μL
reaction mixture containing primers and probes for BALF5 and
B2M supplemented with TaqManTM Universal Master Mix II, no
UNG (Applied BiosystemsTM, Thermo Fisher Scientific). Samples
were run on a QuantStudioTM 5 machine (Applied BiosystemsTM,
Thermo Fisher Scientific) using the following thermal cycle pro-
tocol: 10 min at 95°C followed by 50 cycles of 15 s at 95°C and
1 min at 60°C.
EBV genome copies per 1 × 106 cells were calculated using
standard curves for BALF5 and B2M as analyzed and generated
by the QuantStudioTM Design and Analysis software version 1.4.1.
The standard curves were made by serial dilutions of Namalwa
DNA [27] containing 404 (stock concentration: 132 ng/μL DNA;
assuming that 1 cell contains 6.6 pg DNA and each Namalwa cell
contains two integrated EBV genomes), 104, 103, 200, 40, 10,
4, and 1 EBV genome per μL H2O. The quantity of EBV DNA in
sorted B cells was extrapolated from these curves using CT val-
ues measured in each experiment. All samples were measured in
duplicate.
In vitro memory B-cell differentiation assay
Sorted CD27+ memory B cells were cultured under GC-like condi-
tions as previously described [10]. In short, irradiated 3T3-CD40L
cells were seeded on flat-bottom 96-well plates. We added 5 ×
104 memory B cells per well in the presence of human recombi-
nant IL-21 (50 ng/mL; Thermo Fisher Scientific) with and without
human recombinant IFN-γ (50 ng/mL; Peprotech/Bio-Connect,
Huissen, The Netherlands). After 6 days of culture, supernatants
were collected and stored at −80◦C until use for an EBNA-1 IgG
enzyme-linked immunosorbent assay (ELISA). The cultured cells
were removed and extracellularly stained using flow cytometry as
described above.
Anti-EBNA1 IgG ELISA
A commercially available ELISA kit (IBL international, Hamburg,
Germany) was used to quantify anti-EBNA-1 IgG antibodies in
memory B-cell culture supernatants. Note that 50 μL of each sup-
plied standard and culture supernatants were added to the plate
and incubated for 60 min at room temperature (RT). After wash-
ing, samples were incubated with rabbit peroxidase-conjugated
IgG for 30 min at RT. Each well was incubated with TMB sub-
strate solution for 20 min at RT and the reaction was stopped with
TMB solution. Optical densities were measured at 450 nm using a
BioTek Synergy 2 machine (Winooski, Vermont, USA). Data were
analyzed by following the manufacturer’s instructions. A cut-off
value for culture supernatants was determined based on the aver-
age from cultured naive mature B cells (n = 8). Results above
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≥1.59 U/mL were considered positive, which was the case for 13
out of 21 samples.
Statistical analysis
Statistical analyses on datasets were carried out using GraphPad
Prism Software, version 8 (GraphPad Software, San Diego, CA)
and indicated in figure legends. Data are depicted as the mean ±
standard error of the mean or 95% confidence intervals for corre-
lations. Probability values < 0.05 were considered significant.
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